MARKET

HCM

HCM

Hutchmed (China) Limited
NASDAQ
13.65
+0.32
+2.40%
After Hours: 13.65 0 0.00% 16:10 01/02 EST
OPEN
13.27
PREV CLOSE
13.33
HIGH
13.91
LOW
13.27
VOLUME
62.38K
TURNOVER
--
52 WEEK HIGH
19.50
52 WEEK LOW
11.51
MARKET CAP
2.38B
P/E (TTM)
5.10
1D
5D
1M
3M
1Y
5Y
1D
HUTCHMED Announces NDA Acceptance In China For Savolitinib In MET-Amplified Gastric Cancer
NASDAQ · 12/30/2025 14:49
Hutchmed announces savolitinib new drug application acceptance in China
TipRanks · 12/30/2025 10:10
China NMPA Grants Priority Review to HUTCHMED's Savolitinib NDA for MET-Amplified Gastric Cancer
Reuters · 12/30/2025 10:00
HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA WITH PRIORITY REVIEW STATUS FOR SAVOLITINIB FOR THE TREATMENT OF GASTRIC CANCER PATIENTS WITH MET AMPLIFICATION
Reuters · 12/30/2025 10:00
HUTCHMED's Fanregratinib Receives Priority Review In China For FGFR2 Cholangiocarcinoma- Update
NASDAQ · 12/29/2025 12:13
Hutchmed's NDA For Fanregratinib In Intrahepatic Cholangiocarcinoma Accepted In China
NASDAQ · 12/29/2025 10:17
Weekly Report: what happened at HCM last week (1222-1226)?
Weekly Report · 12/29/2025 10:05
Hutchmed announces fanregratinib NDA acceptance in China with priority review
TipRanks · 12/29/2025 10:05
More
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Webull offers HUTCHMED (China) Ltd (ADR) stock information, including NASDAQ: HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.